Implant Approved for Patients With Phototoxic Reactions From Rare Disorder

WEDNESDAY, Oct. 9, 2019 — The U.S. Food and Drug Administration has approved Scenesse (afamelanotide), a melanocortin-1 receptor agonist, for adult patients with a history of phototoxic reactions from erythropoietic protoporphyria, the agency…
Source: Topamax